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Abstract 
For more than 100 years, innovative drug development has been performed mainly by organic synthetic 
chemistry. In recent years, drug development has shifted to new areas such as molecular targeting drugs. Cancer 
immunotherapy is one of the most attractive targets for new drug discovery. Because immunotherapy is based on 
the stimulation of a patient’s own immune system, it is believed to be patient friendly. However, there are several 
hurdles in developing bioactive proteins for immunotherapy because of the severe systemic toxicities, called 
“immune-related adverse events”, caused by their conventional injection formulations [1-5]. For example, 
interleukin-12 (IL-12) has the significant antitumor activity, however the administration of IL-12 by the 
conventional formulations resulted in excessive systemic toxicities including deaths in a clinical trial [1, 6]. The 
severe adverse effects prevent administration of an effective dose of IL-12 as an antitumor immune therapeutics 
[7]. 
Local delivery is an attractive approach to achieve the therapeutic concentration of bioactive proteins in the 
tumor microenvironment, avoiding an excess of maximum tolerated dose [8-10]. In order to improve controlled 
protein local delivery, several trials such as those with protein/polymer mixtures have been reported. However, 
these approaches are not well established due to the limited extension of retention time at the injection site and 
low mechanical strength [11, 12]. Injectable stimuli-responsive hydrogels are one of the promising candidates for 
local protein delivery because they are flowable as aqueous solutions before administration. Once the flowable 
solution is injected subcutaneously, it immediately converts to gel. Hydrophobic-hydrophilic-hydrophobic 
(ABA-type triblock) copolymers as a matrix for an injectable gel system have been widely studied for the 
controlled release of drugs [12]. However, it is difficult to encapsulate charged drugs effectively in the gel and 
provide sustained releases of them by using this type of copolymers because of poor interactions between 
hydrophobic chains in the copolymers and charged drugs [13-15]. 
Recently our research group has developed and reported a redox-active injectable gel (RIG) system by 
using poly[4-(2,2,6,6-tetramethylpiperidine-N-oxyl)aminomethylstyrene]-b-poly-(ethylene 
glycol)-b-poly[4-(2,2,6,6-tetramethylpiperidine-Noxyl) aminomethylstyrene] (PMNT−PEG−PMNT) triblock 
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copolymer, which possesses reactive oxygen species (ROS) scavenging nitroxide radicals as side chains on the 
PMNT segment. The cationic PMNT segment in PMNT−PEG−PMNT forms polyion complexes (PIC) with 
anionic poly(acrylic acid) (PAAc) to form flower-like micelles, which exhibit temperature- and ionic 
strength-responsive irreversible gelation under physiological conditions. The RIG showed a suppression of ROS 
induced adverse events such as an inflammation related to oxidative stress by ROS scavenging molecules in the 
side chains of PMNT-PEG-PMNT in the RIG [16]. 
In this study, to solve these issues, the author designed and developed protein-loaded, redox-active, 
injectable, gel (RIG) formed by a polyion complex (protein@RIG) for an ideal local protein therapy, which is 
formed by a polyion complex (PIC) comprising three components, viz., cationic polyamine-poly(ethylene 
glycol)-polyamine triblock copolymer possessing ROS-scavenging moieties as side chains (PMNT-PEG-PMNT); 
anionic poly(acrylic acid) (PAAc); and a protein (Figure 1). Since the driving force for the formation of the PIC 
flower micelle is electrostatic interaction, it was expected that the micelle could encapsulate charged compounds, 
including proteins and peptides, and suppress rapid diffusion of the encapsulated compounds by causing the gel 
formation in vivo. One of the other features of the PIC-flower micelle is the elimination of ROS by the gel itself. 
Since nitroxide radicals, which served as a side chain of the PMNT segment in the block copolymer by forming 
covalent bonds, catalytically eliminate ROS, it was anticipated that the redox-active injectable gel system could 
suppress ROS-induced adverse events [16, 17]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1. Schematic illustration of protein-loaded redox-active injectable gel (RIG). Polyion complex (PIC) 
flower micelles are formed by self–assembly via electrostatic interaction between cationic 
polyamine-poly(ethylene glycol)-polyamine triblock copolymer (PMNT-PEG-PMNT) possessing nitroxide 
radicals, which eliminate reactive oxygen species (ROS), as side chains of polyamine segments, anionic 
poly(acrylic acid), and protein. Protein-loaded PIC flower micelle solution shows irreversible sol−gel 
transition with increasing temperature and ionic strength. RIG can provide prolonged retention of the protein at 
a local site and a sustained release of the protein without a significant initial burst owing to ionic interactions 
between the charged polymers and the protein. 
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The material properties of dual stimuli-responsive redox-active injectable gel (RIG) by polyion complex 
based flower micelles was investigated in detail. Cationic PMNT-PEG-PMNT and anionic PAAc formed polyion 
complexes (PIC) flower micelles without aggregation, which was confirmed by dynamic light scattering (DLS) 
measurement and fluorescence resonance energy transfer (FRET) analysis. The author confirmed that the PIC 
flower micelles exhibited irreversible sol-gel phase transitions with increasing both temperatures and ionic 
strengths by rheological evaluation using a rheometer. The PIC flower micelles had a low viscosity at room 
temperature. The viscosity increased with increasing temperatures and ionic strengths, and the RIG was formed 
under physiological condition. The RIG was able to provide sustained release of an anionic model drug for more 
than 4 weeks without an initial burst. 
The author designed and developed a long-acting, protein-loaded, redox-active, injectable gel formed by a 
polyion complex for local protein therapeutics. The author evaluated the material properties of the protein-loaded 
RIG / PIC flower micelles using various types of proteins with different molecular weight and isoelectronic point. 
The protein-loaded PIC flower micelles exhibited sol−gel phase transition with increasing temperature and formed 
the gel under physiological condition. The RIG was able to incorporate various kinds of proteins and provide a 
sustained release of the protein without a significant initial burst regardless of protein types in vitro, and much 
longer retention of the protein at the local injection site in mice than the naked protein. The IL-12-loaded RIG 
showed remarkable tumor growth inhibition in tumor-bearing mice, compared to the naked IL-12, when 
administrated by subcutaneous injection at the adjacent site to the tumor. In addition, IL-12-loaded RIG 
suppressed lymphopenia and the increase of TNF-α level in the liver of the mice, which were caused by IL-12–
induced ROS. 
In this thesis, the author revealed that protein-loaded RIG had the potential as a platform technology for an 
injectable sustained release carrier for proteins to provide high therapeutic effect with suppressing the adverse 
effects. 
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